Last reviewed · How we verify
NCT04989400
Use of Ulipristal Acetate in Induction of Second Trimester Missed Abortion
Phase 4 trial testing Ulipristal Acetate in Induction of Second Trimester Abortion in 24 participants. Completed in 1 January 2020.
1 October 2019
Quick facts
| Lead sponsor | Ain Shams University |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 24 |
| Start date | 1 January 2019 |
| Primary completion | 1 October 2019 |
| Estimated completion | 1 January 2020 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Ulipristal Acetate — full drug profile →
- Misoprostol (Misoprostol) — full drug profile →
Conditions studied
- Induction of Second Trimester Abortion — all drugs for Induction of Second Trimester Abortion →
Sponsor
Ain Shams University
Who can join
Eligibility, female only, with Induction of Second Trimester Abortion. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this work is to assess the effectiveness and safety of Ulipristal Acetate in the management of 2nd trimester missed abortion along with misoprostol in pregnant women with previous caesarean section versus the use of misoprostol only with placebo as regards the time needed for abortion,Hypothesis: In pregnant women with 2nd trimester missed abortion with previous caesarean section , Ulipristal Acetate may decrease the time interval to achieve abortion when combined with Misoprostol in comparison to misoprostol alone.the included women divided to 2 groups Group A: will receive Ulipristal acetate 30mg, starting misoprostol 12 hours later 100µg every 6 hours buccal according to FIGO guidelines 2017.Group B: will receive placebo then 12 hours later start misoprostol 100µg every 6 hours buccal according to FIGO guidelines 2017. then we assess Induction-to-abortion interval time.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04989400
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ulipristal Acetate
Trials testing the same drug.
- NCT07434128 — Mammogram Pretreatment With Ulipristal Acetate · Phase 2 · not yet recruiting
- NCT05285605 — Advance Provision of Postpartum Emergency Contraception and Its Effects on Reproductive Autonomy · completed
- NCT04004884 — Liver Safety Assessment During Ulipristal Acetate Treatment for Uterine Fibroids (LISA) · terminated
- NCT03802149 — Ulipristal Acetate for Cervical Preparation · EARLY_PHASE1 · completed
- NCT03537768 — Study Comparing Emergency Contraception Effectiveness in Women Who Weight ≥ 80 kg · Phase 4 · terminated
Other Ain Shams University trials
Trials by the same sponsor.
- NCT07435493 — Fentanyl Versus Opioid Free Multimodal Analgesia for Perioperative Pain Control in Children With Mild to Moderate Obstru · NA · not yet recruiting
- NCT07482540 — Role of Dexmedatomidine Drug in Prevention of Atrial Fibrillations Post Mitral Valve Surgery · NA · not yet recruiting
- NCT07531030 — Posterior Pericapsular Deep Gluteal Block Combined With Pericapsular Nerve Group and Lateral Femoral Cutaneous Nerve Blo · NA · not yet recruiting
- NCT06839027 — Arterial to Central co2gap in Relation to Outcome After Cardiopulmonary Bypass · not yet recruiting
- NCT07516535 — DISS vs FANS in Suction-Assisted RIRS for Medium-Sized Renal Stones · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04989400 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ain Shams University
- Last refreshed: 4 August 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04989400.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing